Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib
Open Access
- 1 December 2006
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 5 (12) , 3052-3061
- https://doi.org/10.1158/1535-7163.mct-06-0185
Abstract
Strains within the genus Salinospora have been shown to produce complex natural products having antibiotic and antiproliferative activities. The biochemical basis for the cytotoxic effects of salinosporamide A has been linked to its ability to inhibit the proteasome. Synthetically accessible salinosporamide A (ML858) was used to determine its biochemical and biological activities and to compare its effects with those of bortezomib. ML858 and bortezomib show time- and concentration-dependent inhibition of the proteasome in vitro. However, unlike bortezomib, which is a reversible inhibitor, ML858 covalently binds to the proteasome, resulting in the irreversible inhibition of 20S proteasome activity. ML858 was equipotent to bortezomib in cell-based reporter stabilization assays, but due to intramolecular instability is less potent in long-term assays. ML858 failed to maintain levels of proteasome inhibition necessary to achieve efficacy in tumor models responsive to bortezomib. Our results show that ML858 and bortezomib exhibit different kinetic and pharmacologic profiles and suggest that additional characterization of ML858 is warranted before its therapeutic potential can be fully appreciated. [Mol Cancer Ther 2006;5(12):3052–61]Keywords
All Related Versions
This publication has 38 references indexed in Scilit:
- A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from BortezomibCancer Cell, 2005
- The aggravating role of the ubiquitin–proteasome system in neurodegenerationFEBS Letters, 2005
- Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitroLeukemia, 2004
- A Simple Stereocontrolled Synthesis of Salinosporamide AJournal of the American Chemical Society, 2004
- Salinosporamide A: A Highly Cytotoxic Proteasome Inhibitor from a Novel Microbial Source, a Marine Bacterium of the New Genus SalinosporaAngewandte Chemie International Edition in English, 2003
- Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic MalignanciesJournal of Clinical Oncology, 2002
- A Novel and Efficient Synthesis of a Highly Active Analogue of clasto-Lactacystin β-LactoneJournal of the American Chemical Society, 1999
- THE UBIQUITIN SYSTEMAnnual Review of Biochemistry, 1998
- How Proteolysis Drives the Cell CycleScience, 1996
- Mechanistic Studies on the Inactivation of the Proteasome by LactacystinJournal of Biological Chemistry, 1996